Uncategorized
SHP607 reduces BPD, IVH among premature infants in phase 2 trial
SHP607, a recombinant human version of insulin-like growth factor 1 and IGF binding protein-3 from Shire, effectively reduced development of severe bronchopulmonary dysplasia and severe intraventricular hemorrhage among extremely preterm infants, according to recent phase 2 findings.The investigational protein replacement, however, did not meet its primary endpoint of effectively reducing the severity of retinopathy, a rare eye condition that occurs in extremely preterm neonates. The secondary endpoints, of reducing bronchopulmonary dysplasia (BPD) and intraventricular hemorrhage (IVH), were met successfully in the multicenter trial.